#Human Antibody Blocks Dengue virus In Mice Researchers have discovered that a human antibody specific to dengue virus serotype 2,
--and they suggest that the site where 2d22 binds to the virus could represent a potential vaccine target.
and there is currently no protective vaccine available. Recent phase 3 clinical trials of a potential vaccine candidate showed poor efficacy,
especially against dengue virus serotype 2. Guntur Fibriansah and colleagues found that 2d22 protects mice against dengue virus serotype 2,
researchers at Boston Children's Hospital and Harvard Medical school have restored hearing in mice with a genetic form of deafness.
a specialist in genetic hearing loss at Boston Children's Hospital who is familiar with the work."
The idea came to University of Guelph public health researcher Christopher Charles, during a trip to Cambodia six years ago,
000 fish have been distributed to hospitals and charity organisations around the country. Being deficient in iron means the body doesn produce enough red blood cells,
and it become one of the biggest challenges facing public health today. But new findings suggest that old,
More recently, researchers at St jude Children Research Hospital in Memphis revisited the drug, with an interest in increasing its potency.
and get it into the hands of people who can't make it to the optometrist clinic-that could be
Vaccines and health clinics can be up and running earlier and any necessary travelling restrictions can be put in place before the situation worsens."
a professor of molecular microbiology and immunology at Johns Hopkins Bloomberg School of Public health in Maryland, told Linn.
whether Wnt inhibition or similar approaches would provide long-term therapeutic value in the clinic.""And while this specific treatment will most likely only work for colon cancer,
"lead researcher Allen C. Ho from the Wills Eye Hospital in Pennsylvania, US, said in a press release."
surgical oncologist David Linehan from the University of Rochester Medical centre in the US told Elaine Schattner at Forbes. The key to the new blood test is a tiny,
#New Ebola vaccine is 100%successful in Guinea clinical trials A new single-dose vaccine has been shown to be 100 percent effective against Ebola after just one week.
Known as VSV-ZEBOV, the vaccine is now going through further trials in younger patients, and if all goes to plan could become the first licensed vaccine against Ebola.
As of right now around 28,000 people in Guinea, Sierra leone and Libera have been infected with Ebola,
A second study group of 3, 528 people were injected with the vaccine three weeks after they'd potentially been exposed to Ebola.
"Indeed, no vaccinee developed symptoms more than six days after vaccination, irrespective of whether vaccination was delayed immediate
the international team of researchers stopped waiting to vaccinate those at high-risk of infection.""The initial results of the study show that the vaccine can effectively contain the further spread of the Ebola virus,"the University of Bern in Switzerland,
which was involved in the research, wrote in a statement.""We believe that the world is on the verge of an efficacious Ebola vaccine,
"World Health Organisation (WHO) vaccine expert Marie Paule Kieny told reporters at a media briefing announcing the results on Friday.
The trial, which was supported by the drug firm Merck, THE WHO and the Canadian, Norwegian and Guinean governments, is now continuing in children between the ages of 13 and 17.
For the last century medical research including public health advances has been the primary source of and an essential contributor to improvement in the health and longevity of individuals and populations in developed countries.
Reduced science investment The largest increase in biomedical and health services research funding in the U s. occurred between 1994 and 2004
and (in real terms) decreased in 3 of the last 5 years reaching $117 billion (4. 5 percent) of total health care expenditures.
From 1994 to 2004 the medical device biotechnology and pharmaceutical industries had annual growth rates greater than 6 percent per year with biotechnology demonstrating the largest increases.
Industry reduced early-stage research favoring medical devices bioengineered drugs and late-stage clinical trials particularly for cancer and rare diseases.
Underfunding of service innovation Health services research (which examines access to care the quality and cost of care and the health and well-being of individuals communities and populations) accounted for between 0. 2 percent and 0. 3 percent of national health expenditures between 2003 and 2011 an approximately 20-fold difference
in comparison with total medical research funding. Private insurers ranked last (0. 04 percent of revenue) and health systems 19th (0. 1 percent of revenue) among 22 industries in their investment in innovation.
In this new study researchers compared 64 healthy control subjects to 75 patients who had experienced trauma that brought them to the emergency department at Bellevue Hospital Center in New york city with
When 11 year old Naomi Lalandec walked into Dr. Robert Koenekoop's clinic at the Montreal Children's Hospital of the Mcgill University Health Centre (MUHC) with blindness and dwarfism due to
#WHO grants approval for safe effective meningitis A vaccine for infants The World health organization (WHO) has opened the door to routine immunization of infants in Sub-saharan africa by approving for use an innovative and affordable vaccine that has all but rid the meningitis belt of a major cause
The announcement was made today by the Meningitis Vaccine Project (MVP)--a partnership between the global health nonprofit PATH and WHO--and Serum institute of india Ltd (SIIL),
which manufactures the Menafrivac vaccine.""Initial mass vaccination campaigns with Menafrivac have been highly effective in reducing the number of meningitis A cases,
"said Dr. Marie-Pierre Préziosi, director of MVP.""But epidemics will return when rising numbers of unprotected newborns become a larger proportion of the total population over time.
5 g dose of the meningitis A vaccine meets international standards of quality, safety, and efficacy and can
The only existing vaccine was insufficient to break the cycle. Protection at an affordable price In 2004, MVP partnered with SIIL to develop an affordable, tailor-made vaccine for use against meningitis A in Sub-saharan africa.
Menafrivac was developed in record time at less than 1 tenth the cost of a typical new vaccine. Since campaigns started in 2010,
Menafrivac has been administered to over 215 million people in 15 countries of the African meningitis belt:
"Developing the Menafrivac vaccine fit exactly Serum's ingrained philosophy of bringing down prices of vaccines
"We at Serum Institute are extremely proud of being part of an international partnership that brought an end to a public health issue that has been plaguing Sub-saharan africa for more than a century."
"One year after large-scale vaccine introduction in late 2010, for example, experience from Burkina faso provided early evidence that mass vaccination was associated with a significantly reduced risk of meningitis in the targeted population,
Findings were confirmed in a major way in Chad in 2012 where researchers reported a dramatic reduction in transmission and incidence of meningitis A a drop of more than 90 percent following vaccination.
Support from Gavi, the Vaccine Alliance; the United nations children's fund (UNICEF; PATH; WHO; and national governments has been crucial for mass vaccination campaigns that are due to continue until 2016 to cover at-risk populations in all 26 countries where disease burden from meningitis A is greatest.
From mass campaigns to routine immunizations In parallel to the large-scale vaccination campaigns, clinical studies were designed
and conducted to determine the safety, immunogenicity, and optimal dosage and immunization schedule for administering Menafrivac to infants and toddlers alongside other routine childhood vaccines in African meningitis belt countries.
Results from two infant clinical studies in Ghana and Mali and vaccine introduction impact data were presented to THE WHO Strategic Advisory Group of Experts on Immunization (SAGE) in October 2014
and these SAGE experts concluded that a one-dose schedule at 9 months of age or older was recommended to achieve sustainable disease control following the initial mass campaigns in 1-29 year olds.
Specifically, THE WHO prequalification that was announced today allows United nations procurement agencies to purchase the vaccine for use in routine immunization programs in meningitis-belt countries
while mass vaccination campaigns will continue in remaining countries. Created in June 2001 with the goal of eliminating epidemic meningitis as a public health problem in Sub-saharan africa,
MVP was one of the earliest product development partnerships funded by the Bill & Melinda Gates Foundation.
Menafrivac was the first vaccine developed outside"traditional pharma, "and the only vaccine developed specifically for people in Africa."
"With Menafrivac, we created a revolutionary new model for vaccine development and now we stand on the brink of protecting an entire generation,
and those to come, from a devastating disease, "said Dr. Kathy Neuzil, director of Vaccine Access and Delivery at PATH."
"Our efforts began with a request by African leaders to address a major health challenge affecting hundreds of millions of people,
effective vaccine could be developed and deployed across multiple countries at a price that was sustainable.""
""The benefits of childhood immunization last a lifetime and the Menafrivac vaccine is one of the greatest success stories that shows
"Prequalification of the Menafrivac vaccine for infants clears the way for the routine immunization of every child before his
""We are more than halfway through with introducing the vaccine in meningitis-belt countries, and the first introductions have been a stunning success,
"said Dr. Jeanmarie Okwo-Bele, director of THE WHO Department of Immunization, Vaccines and Biologicals.""But we cannot yet declare a win on meningitis epidemics in Sub-saharan africa.
and introduce the vaccine in the Expanded Programme on Immunization. Then and only then will we win the battle against meningitis. a
help them to treat patients more effectively and save health service cash. The development, by researchers at The University of Manchester, will allow noninvasive detection of the origin of heart problems
Using this new algorithm ECG map can help diagnose the location of cardiac disorder in a way which is better for the patients and more cost effective for health services
which is causing a public health crisis, according to Uni ver sity Dis tin guished Pro fessor Kim Lewis. But in new research,
Senegal, the Public health Institute of Guinea, the University of Stirling, Robert Koch Institute, and Twistdx Ltd.
#New approach may lead to inhalable vaccines for influenza pneumonia The work led by Cathy Fromen
In contrast negatively charged particles of the same composition led to weaker and in some cases undetectable immune responses suggesting that particle charge is an important consideration for pulmonary vaccination.
The findings published in the Proceedings of the National Academy of Sciences also have broad public health implications for improving the accessibility of vaccines.
An inhalable vaccine may eliminate the need for refrigeration which can not only improve shelf life but also enable distribution of vaccines to low-resource areas including many developing countries where there is significant need for better access to vaccines s
#Study pinpoints autism-linked protein for sculpting brain connections A new study by Duke researchers provides a close up of synapse refinement
With this information health care workers can then personalize the baby's nutritional supplements to help with appropriate weight gain.
health care workers have performed hundreds of analyses of breast milk. Simmons, the Ruth and Harry Roman Chair in Neonatology in honor of Larry Baum said the information from both analyses should ultimately lead to healthier weight gain, better neurological outcomes and shorter hospital stays
This combination results in multiple health risks including high blood sugar and fatty liver disease. For years to gain insight into this phenomenon researchers focused on the role of altered insulin action in the liver in the production of triglycerides.
a research team led by investigators at Beth Israel Deaconess Medical center (BIDMC) has uncovered previously unknown steps in the development of insulin resistance, a hallmark of type 2 diabetes.
#DNA nanoswitches reveal how life's molecules connect Now a new approach developed by researchers at the Wyss Institute for Biologically Inspired Engineering Boston Children's Hospital
Professor of Vascular Biology at Boston Children's Hospital and Harvard Medical school and a Professor of Bioengineering at Harvard SEAS.
Lee Smith MD chief of pediatric otolaryngology at Cohen Children's Medical center and David Zeltsman MD chief of thoracic surgery at Long island Jewish Medical center both part of
"said co-author Joseph E. Bavaria, MD, from the Hospital of the University of Pennsylvania in Philadelphia."
Results of a Mayo Clinic study comparing the new model to the current standard, the Breast cancer Risk Assessment Tool (BCRAT), are published in the Journal of Clinical Oncology."
for the presence of a breast cancer,"says Amy Degnim, M d.,a surgeon at Mayo Clinic and a senior author of the study."
Dr. Degnim and her colleagues studied a cohort of approximately 10,000 women who had benign breast biopsies at Mayo Clinic
and 734 matched controls sampled from the Mayo Clinic BBD cohort. They validated the model using an independent set of women from the Mayo BBD cohort (378 patients with a later breast cancer
New Molecular Target Identified A drug already approved for treating other diseases may be useful as a treatment for cerebral malaria, according to researchers at Harvard T. H. Chan School of Public health.
both researchers at Harvard T. H. Chan School of Public health, found that leptin--a hormone secreted from fat tissue with roles in suppressing appetite,
About half of all screening-aged women have dense breast tissue according to Deborah Rhodes M d. a Mayo Clinic Breast Clinic physician
The study conducted at Mayo Clinic included 1585 women with heterogeneously or extremely dense breasts who underwent an MBI exam at the time of their screening mammogram.
so our finding of an additional 8. 8 cancers per 1000 women makes MBI a very compelling option for women who elect supplemental screening says Dr. Rhodes. Michael O'connor Ph d. a Mayo Clinic scientist
because it incorporates many of the advances in MBI pioneered here at Mayo Clinic and shows that studies can be performed safely with low radiation exposure to the patient says Dr. O'connor. This means MBI is safe and effective as a supplemental screening tool.
what MBI can offer women with dense breasts says Amy Conners M d. chair of Mayo Clinic's Breast Imaging Division
Abnormalities in these brain regions are associated with neurological and mental health disorders. According to Professor Donohoe: For years scientists have been fascinated by the development of different brain structures and how this changes in brain-based disorders.
of which have recorded astonishingly positive results in the clinic and are able to prolong the lives of seriously sick patients.
Joining forces with dermatologists and oncologists from the University Hospital in Zurich and backed by the University Research Priority Program"Translational Cancer Research,
and health policy colleagues at the Urban Institute, utilized trained field staff, posing as Medicaid and privately insured patients seeking new-patient primary care appointments, calling offices in two
Reductions of that magnitude would offset some of the gains in appointment availability identified in this new study,"observed Stephen Zuckerman, co-director of the Urban Institute's Health policy Center r
Empa and the University Hospital Zurich thus teamed up to develop the sensor"Glucolight,""which gages the blood sugar level through the skin,
and the first clinical studies are scheduled at the University Hospital Zurich for 2015. However it could be years before the use of Glucolight becomes standard.
Empa and the University Hospital Zurich are currently in negotiations with partners for the industrial production of the sensor.
and possibly the overall aging process. said Audrey Tyrka MD Phd Director of the Laboratory for Clinical and Translational Neuroscience at Butler Hospital and Associate professor of Psychiatry and Human Behavior at Brown University.
assistant professor of regenerative medicine at Wake Forest Baptist Medical center and a co-inventor of the system. ut how do they know when theye removed enough tissue?
in addition to the inventors, were James M. Provenzale, M d.,Duke university Medical center and Emory University; and Corey F. Saba, D. V. M.,Karen K. Cornell, D. V. M.,Ph d,
Wake Forest Baptist Medical center (www. wakehealth. edu) is recognized a nationally academic medical center in Winston-salem, N c,
. with an integrated enterprise including educational and research facilities, hospitals, clinics, diagnostic centers and other primary and specialty care facilities serving 24 counties in northwest North carolina and southwest
and gene therapy, said Daiger, the report's senior author and holder of the Thomas Stull Matney Ph d. Endowed Professorship in Environmental and Genetic sciences at UTHEALTH School of Public health."
"For approximately three decades, Daiger, a member of the Human genetics Center at the UTHEALTH School of Public health, has been following the progress of hundreds of families across the country with retinitis pigmentosa."
But what we found was that in most cases including the reaction to a standard influenza vaccine
or toxic exposures vaccinations diet and dental hygiene--trumped heritable ones when it came to accounting for differences within a pair of twins.
Davis and his associates also observed considerable environmental influence over the quantities of antibodies produced in members of twin pairs who had been vaccinated for influenza in a separate Stanford investigation directed by study co-author Cornelia Dekker MD professor of pediatric infectious disease
and medical director of the Stanford-Lucile Packard Children's Hospital Vaccine Program. While many previous studies have suggested a powerful genetic component in vaccine responsiveness Davis noted that those studies typically were performed in very young children who had undergone not yet the decades of environmental exposure that appears to reshape the immune system over time.
In a striking example of the immune system's plasticity the Stanford scientists found that the presence
a team of biomedical engineering undergraduates has developed a kit to teach front-line health care workers in developing countries how to implant contraceptives.
when they actually perform these procedures in a clinic, "said rising junior Miguel Sobral, a team member from Lisbon, Portugal.
the student inventors were advised by physician Ricky Lu, technical director for reproductive health and family planning at Jhpiego,
"says the researcher from the University of Bonn Hospital. Simplified test to test novel viruses for risk of human infection Triggered by epidemics such as SARS and Ebola,
in association with Montpellier Regional University Hospital and Stanford university, have transformed bacteria into"secret agents"that can give warning of a disease based solely on the presence of characteristic molecules in the urine or blood.
and require sophisticated technologies that are often available only in hospitals. This is where biological systems come into play.
in association with Professor Eric Renard (Montpellier Regional University Hospital) and Drew Endy (Stanford university), applied this new technology to the detection of disease signals in clinical samples.
Cancer researchers have been interested in these proteins as markers for cancer and as potential targets for therapeutic cancer vaccines."
Multiple hospitals have agreed to provide blood samples for analysis to Wistar for this next study."
"We have designed a vaccine-style treatment or'immunotherapy'specifically for individuals carrying high-risk rheumatoid arthritis genes and specific rheumatoid arthritis antibodies, called anti-CCP."
clinically-practical vaccine technology that could deliver similar outcomes for patients. Professor Thomas is working on a delivery technology with Dendright Pty Ltd (a Uniquest start-up company) in collaboration Janssen Biotech Inc,
Stephen Elledge, an HHMI investigator at Brigham and Women's Hospital, led the development of Virscan."
either through infection or through vaccination. Elledge estimates it would take about 2-3 days to process 100 samples,
Their findings on viral epitopes may also have important implications for vaccine design. Elledge says the approach his team has developed is limited not to antiviral antibodies.
which is still the gold standard in the health care industry for making a definitive diagnosis. Also routinely used today is a newer method for rapidly identifying bacteria based on a DNA-analysis technique called quantitative polymerase chain reaction (qpcr),
"Why Speed Matters in Infection Control In hospitals and clinics worldwide, bacterial infections are a major source of illness,
For that reason, many hospital-acquired infections are treated presumptively, before they are identified definitively, using broad-spectrum antibiotics.
and improving outcomes for people with hospital-acquired infections--though the effectiveness of the approach remains to be proven in future clinical trials.
In addition to helping in the clinic the new method may be useful in the food industry or for homeland security applications.
Dr. Oliver Eickelberg and Dr. Claudia Staab-Weijnitz of the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum München and their colleagues at LMU University Hospital in Munich and Yale university
has already been tested on a small sample of patients at the La paz University Hospital and in ex vivo tissues of animal models.
a consortium that wants to boost the collaboration between research centres and hospitals in the autonomous community of Madrid with the Massachusetts institute of technology (MIT) and other institutions in the Boston area (USA.
"We witnessed a LP on a 29-day-old baby that had arrived at the accident and emergency department at Boston Children's Hospital with a fever.
Madrid hospitals La paz, Quirón and San Carlos also provided significant assistance. In Boston, they worked with Massachusetts General Hospital.
Arrayto date, 300,000 euros has been invested in the project, awarded by the Madrid-MIT M+Visión Consortium.
#Disrupting tumor cell'microenvironment'suggests a new way to treat a prevalent childhood leukemia Researchers at NYU Langone Medical center
who has started already this work as a guest researcher at the Sahlgrenska Academy Hospital in Sweden."
working with colleagues at the Erasmus Medical centre in Rotterdam, have identified individual stem cells that can regenerate tissue, cartilage and bone.
#Cellular mechanism for how the body regulates glucose transport discovered UT Southwestern Medical center scientists have gleaned a key cellular mechanism of how the body adjusts glucose levels,
a gynaecologist and research associate in the Fertility Clinic and Research Laboratory on Human Reproduction at Erasme Hospital, Université Libre de Bruxelles (Brussels,
fatigue and in many cases can result in a reduction of quality of life, time off work, hospitalisations and surgery.
UEG's inflammatory bowel disease expert, Dr Charles Murray of the Royal Free Hospital, London, UK comments;"
In order to use protein detection for diagnostic purposes, e g. in a clinic, new, less complicated methods to study proteins are needed.
and commonly available in hospital and research labs. Since two antibodies are bound in the first step alsesignals can be avoided,
#New mechanism that attacks viral infections discovered An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical centers in Mainz and Freiburg.
"explained Professor Andreas Diefenbach of the Department of Medical microbiology and Hygiene of the Mainz University Medical center.
#Protein discovery fuels redesign of mosquito-based malaria vaccine A promising type of vaccine designed to eradicate malaria by blocking parasite transmission could be a step closer,
and Dr Rhoel Dinglasan from the Malaria Research Institute at the Johns Hopkins Bloomberg School of Public health in Baltimore, USA, focused on a protein in the Anopheles mosquito midgut called Anapn1.
Malaria transmission-blocking vaccines are designed to prevent the spread of malaria by interrupting parasite transmission.
Vaccinated individuals in malaria-endemic countries produce antibodies to Anapn1. During routine disease transmission, when these same immunised individuals become infected with malaria parasites,
The Anapn1 protein is a leading candidate for a mosquito-based malaria transmission-blocking vaccine that is being developed by Dr Dinglasan."
"This type of vaccine won't boost people's immunity to malaria, but instead it will provide a delayed benefit to the individual by protecting the entire community from parasite transmission,
Dr Dinglasan said as a vaccine antigen, Anapn1 prompts people to make antibodies; however only some of these antibodies block parasite transmission,
To further improve vaccine immunogenicity at the preclinical stage, we need to immuno-focus the antibody response to only the critical,
"Nearly all of the participants in our study had blood markers identical to patients admitted to hospital with sepsis.
researchers from Erasmus Medical center in The netherlands used a biodegradable material called Polyactive, which keeps proteins intact,
The document, published in the Lancet June 16 and signed by the Johns Hopkins Bloomberg School of Public health's Alain Labrique and six others, states that the conditions in the April tremor that killed 8
when infected by the virus. There is a safe and effective vaccine available, the researchers say,
if the vaccine were used in Nepal during monsoon season, which runs from July to September.
that the Nepalese Ministry of Health should initiate a request for the vaccine and build a stockpile;
and develop targeted deployment strategies for the use of the vaccine, based on identification of high-risk populations and the available organizational capacity for safe implementation and monitoring of outcomes."
. a Mayo Clinic oncologist and lead author of the study.""We believe we have identified a mechanism that seizes the cancer's biological engine
"These findings now explain why it is difficult to develop vaccines against tuberculosis, "said Dr. Das."
"The immune cells activated by the vaccine agent may not be able to reach the hypoxic site of bone marrow to target these"wolfs-in-stem-cell-clothing."
#Discovery promises new treatments to thwart colon cancer Scientists at St jude Children's Research Hospital have discovered how an immune system protein,
#Cell that replenishes heart muscle found by researchers Regenerative medicine researchers at UT Southwestern Medical center have identified a cell that replenishes adult heart muscle by using a new cell lineage-tracing technique they devised.
and will now be tested in a larger trial involving three hospitals in London. Researchers analysed breath samples of 210 patients using the test.
Now, 400 patients at UCLH (University college London Hospitals NHS Foundation Trust), The Royal Marsden NHS Foundation Trust,
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011